Artificial Intelligence (AI) for the early detection of breast cancer: a scoping review to assess AI’s potential for screening practice.
Metadata
Show full item recordType
ArticleAbstract
Various factors are driving interest in the application of artificial intelligence (AI) for breast cancer (BC) detection, but it is unclear whether the evidence warrants large-scale use in population-based screening.
We performed a scoping review, a structured evidence synthesis ...
See moreVarious factors are driving interest in the application of artificial intelligence (AI) for breast cancer (BC) detection, but it is unclear whether the evidence warrants large-scale use in population-based screening. We performed a scoping review, a structured evidence synthesis describing a broad research field, to summarize knowledge on AI evaluated for BC detection and to assess AI’s readiness for adoption in BC screening. Studies were predominantly small retrospective studies based on highly selected image datasets that contained a high proportion of cancers (median BC proportion in datasets 26.5%), and used heterogeneous techniques to develop AI models; the range of estimated AUC (area under ROC curve) for AI models was 69.2–97.8% (median AUC 88.2%). We identified various methodologic limitations including use of non-representative imaging data for model training, limited validation in external datasets, potential bias in training data, and few comparative data for AI versus radiologists’ interpretation of mammography screening.
See less
See moreVarious factors are driving interest in the application of artificial intelligence (AI) for breast cancer (BC) detection, but it is unclear whether the evidence warrants large-scale use in population-based screening. We performed a scoping review, a structured evidence synthesis describing a broad research field, to summarize knowledge on AI evaluated for BC detection and to assess AI’s readiness for adoption in BC screening. Studies were predominantly small retrospective studies based on highly selected image datasets that contained a high proportion of cancers (median BC proportion in datasets 26.5%), and used heterogeneous techniques to develop AI models; the range of estimated AUC (area under ROC curve) for AI models was 69.2–97.8% (median AUC 88.2%). We identified various methodologic limitations including use of non-representative imaging data for model training, limited validation in external datasets, potential bias in training data, and few comparative data for AI versus radiologists’ interpretation of mammography screening.
See less
Date
2019Source title
Expert Review of Medical DevicesVolume
16Issue
5Publisher
Taylor and FrancisFunding information
National Breast Cancer Foundation (NBCF)
Safeway Foundation
Licence
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0Faculty/School
Faculty of Medicine and Health, Sydney School of Public HealthShare